Effect of gut microbiota modulation on feeding tolerance of enterally-fed critically ill adult patients: a systematic review

Najmeh Seifi
Mashhad University of Medical Sciences

Ali Jafarzadeh Esfahani
Mashhad University of Medical Sciences

Alireza Sedaghat
Mashhad University of Medical Sciences

Reza Rezvani
Mashhad University of Medical Sciences

Majid Khadem-Rezaiyan
Mashhad University of Medical Sciences

Mohsen Nematy
Mashhad University of Medical Sciences

Mohammad Safarian
Mashhad University of Medical Sciences

Research

Keywords: prebiotics, probiotics, synbiotics, gut microbiota, feeding tolerance, critical care

DOI: https://doi.org/10.21203/rs.3.rs-26095/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose: The objective of this systematic review was to evaluate the effect of pre-, pro-, and synbiotics on feeding tolerance of enterally-fed critically ill adult patients.

Methods: Medline, Science Direct, Web of Knowledge, and the Cochrane Central Register of Controlled Trials were searched up to November 2019. English language randomized controlled trials reporting the effect of pre, pro or synbiotics on the feeding tolerance of enterally-fed critically ill adult patients were included.

Results: Overall, 15 papers were selected for review. Among six studies reporting the energy intake, only two studies showed significantly higher energy intake in the prebiotic-receiving groups. Among four RCTs reporting frequency or time to achieve the target calorie, only one found a significant effect of probiotics to reduce the time to achieve a target dose of calorie. About the prevalence or duration of diarrhea, 7 out of 12 RCTs reported a beneficial effect. All but one study found no beneficial effects for gut microbiota manipulation on clinical endpoints including length of stay (LOS) in hospital and intensive care unit (ICU).

Conclusion: It should be noticed that the heterogeneity in study designs, product format, and ICU patient populations makes it difficult to draw any general conclusion. Overall, it seems that pre, pro or synbiotics have not significant beneficial effect on feeding tolerance and clinical endpoints in critically ill adults, but they may reduce the prevalence or duration of diarrhea.

Background

Critical illness can cause hypermetabolism and hypercatabolic state that quickly depletes nutritional reserves, alters immune function and predisposes individuals to morbidity and mortality (1, 2). Critically ill patients are also likely to experience severe changes in gut function. These changes are due to alterations in gut muscle contractions, secretion, and absorption. Gut microbiota disturbances and epithelial barrier disintegration are also involved (3-5). In this situation, early-onset and the proper amount of nutrition support are of great importance (6). Enteral nutrition (EN) is regarded as the favored root of nutrition support, because it protects the gut barrier, modulates immune responses, and leads to a faster return of gut function. However, many critical care patients cannot receive EN due to tolerance problems (4, 6).

Enteral feeding intolerance is a common problem among critical care patients. It is often defined as either or both of the following conditions; reduced delivery of EN and presence of gastrointestinal (GI) symptoms, including diarrhea, vomiting, regurgitation, abdominal distention, and high gastric residual volume (GRV) (7). Feeding intolerance often results in failure to achieve the target nutritional dose as well as increased risk of pneumonia and intensive care unit (ICU) stay (8). Factors associated with feeding intolerance in critically ill patients include stress-induced hyperglycemia, hormonal disturbances (including high levels of cholecystokinin (CCK), and peptide YY (PYY), and low levels of motilin), administration of sedatives, analgesics, and vasopressor agents, and disturbances in gut microbiota. These factors finally result in gastrointestinal dysfunction and manifest as feeding intolerance (9).

Gut microbiota manipulation can affect enteral feeding tolerance and energy homeostasis through several mechanisms. Administration of pre, pro, or synbiotics are different ways of gut microbiota manipulation. Probiotics are live microorganisms that have beneficial health effects if administered in optimum amounts. Prebiotics are non-digestible oligosaccharides that promote growth and/or activity of specific bacteria in the gut. Synbiotics are products with a combination of probiotics and prebiotics (10). Altering gut muscle contractions, secretion, and absorption (11-13), regulating glucose homeostasis (14, 15), as well as affecting hormonal and immune responses, host metabolism, and feeding behavior (16) are known mechanisms by which gut microbiota modulation can affect feeding tolerance and energy homeostasis.

Recently, the relationship between gut microbiota and nutrition, especially in critically ill patients has been attracting considerable interest. Many studies have reported the effect of pre, pro, or synbiotics on EN volume, energy intake, or EN associated complication. Nevertheless, to the best of our knowledge, no systematic review or meta-analysis has been conducted to evaluate the effect of pre-, pro-, and synbiotics on feeding tolerance of enterally-fed critically ill adult patients.

Methods

This systematic review was consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (Additional file1) (17).

3.1 Search strategy

A systematic search of randomized controlled trials published until November 10, 2019 was independently conducted by two authors (NS, AJE) on Medline (via PubMed), Science Direct (via Scopus and Embase), Web of Knowledge (via Web of Science) and the Cochrane Central Register of Controlled Trials (via Cochrane Library). The search strategy was designed in accordance with the database orientations using boolean operators (AND, OR), parenthesis, quotation marks and asterisks. The following search strategy was used in Medline: (“critical*”) OR “critical care” OR “critical illness” OR “critically ill” OR “critically unwell” OR “severely unwell” OR “severely ill” OR “intensive care” OR “ICU” OR “CCU”) AND (“tube feeding” OR “enteral*” OR “enteral feeding” OR “enteral nutrition” OR “force-feeding” OR “nasogastric*” OR “nasoduodenal*” OR “nasojugal*”) AND (prebiotic* OR probiotic* OR symbiotic* OR symbiotic) NOT (child OR pediatric OR infant OR preterm OR neonate) AND (“Enteral Nutrition”[Mesh]) AND (“Critical Care”[Mesh]) OR (“tolerance” OR “intolerance” OR “tolerant” OR “intolerant”) OR (“diarrhea” OR “diarhoea” OR “distension” OR “distent*”) AND (“Probiotics”[Mesh] OR “Synbiotics”[Mesh] OR “Prebiotics”[Mesh])
Language restriction was applied to select articles in English. Furthermore, a manual reference check was conducted on the identified articles to find further relevant studies.

3.2 Screening and eligibility of records

The population, intervention, comparison, outcome and study design (PICOS) strategy was used to identify inclusion criteria. The title and abstract of all identified articles were independently screened by two authors (NS, AJE). Randomized controlled trials that assessed the effect of pre, pro and synbiotics on feeding tolerance in tube-fed critically ill patients were selected. The full text of selected articles was read and assessed regarding compliance with established eligibility criteria. Discrepancies were resolved by discussion with a third researcher (RR).

3.3 Data extraction and synthesis

The following variables were considered in data extraction: title, authors, year, country, study aim, population features (sex, age, number of participants), experimental design, intervention (the composition of prebiotic, probiotic and synbiotic, dose, and timing of administration), and main results.

3.4 Risk of bias assessment

The five-point JADAD score was used independently by two authors (NS, AJE) to assess the quality of included studies. Discrepancies were resolved by discussion with a third researcher (MKR). The five domains of the JADAD score included being randomized, appropriately describing of randomization, being double-blind, appropriately describing blinding, and explanation of withdrawal and dropouts.

3.5 Clinical outcomes

In this study, feeding intolerance was defined as either or both of the following conditions; reduced delivery of EN and presence of gastrointestinal (GI) symptoms, including diarrhea, vomiting, regurgitation, abdominal distention, and high gastric residual volume (GRV). So, the clinical outcomes of interest were enteral feed volume, energy intake, which correlates with feed volume, time to reach full enteral nutrition, the prevalence of feed intolerance, and related GI complications (diarrhea, distention, high residual volume). Length of stay (LOS) in the ICU or hospital was investigated as a secondary outcome.

Results

4.2 Effect on energy intake and feed volume

Six trials examined the effect of pre, pro, or synbiotics on energy intake or feed volume in critically ill patients.

4.2.1. prebiotics

In one trial in 2000, 44 critically ill patients receiving EN and antibiotics were randomized to receive fiber-containing or fiber-free formula and pectin or placebo for six days. Mean energy intake ranged from 1200 kcal on day 1 to 1563 kcal on day 5. Mean energy or protein intake was not significantly different in the four study groups (19). Rushdi et al. also evaluated the effect of guar gum enriched formula in 20 critically ill tube-fed patients with persistent diarrhea for four days. They showed that patients in the intervention group tolerated significantly higher formula volumes on days 1, 2, and 4. On the fourth day, the feed volume was 1775±450 ml in the intervention group compared to 1070±604 ml in the controls (p<0.01) (21). In 2018, Fazilaty et al. evaluated the effect of EN containing β-glucan on inflammatory markers and clinical outcomes. They reported no significant difference in the mean tolerated calories between study groups (1710.5±117.03 kcal vs. 1718.2±182.4 kcal, p=0.6) (30). Tuncay et al. compared the effect of an enteral formula enriched with prebiotic versus standard EN on nutritional parameters among 46 neurocritically ill patients. Results showed that feed volume and mean energy intake significantly increased from baseline to day 21 in both groups. Patients in the intervention group tolerated a significantly higher amount of energy and feed volume on day 1 and 21 (32).

4.2.2. probiotics

In a trial conducted in 2014, 40 critically ill patients were randomly assigned to receive a multi-strain probiotic or placebo for seven days. Results showed no significant difference between groups in terms of the mean energy intake (1503.75±231.6 kcal vs. 1617.5±185.51 kcal, p= 0.09). The percentage of patients who met energy requirements in the synbiotic and placebo groups was 84.98±3.6 and 87.24±3.92, respectively (p=0.06) (27).

4.2.2. synbiotics

Knight et al. investigated the effect of enteral synbiotic on ventilator-associated pneumonia in critically ill patients. They reported an increase in the daily tolerated feed volume from day 1 to 7 in both groups. The feed volume ranged from 488.9± 622.8 ml on day 1 to 1055.6±722.6 ml on day 7 in the synbiotic group and from 360±431.7 ml to 1243.9±810.3 ml in the placebo group. There was no significant difference between the two groups regarding the mean tolerated enteral feed volume (22).

4.3 Effect on target calorie achievement

Four trials assessed the effect of prebiotics or probiotics on the prevalence of target calorie achievement or time to receive the target calorie.

4.3.1. prebiotics
In a trial conducted in 2001, severe sepsis or septic shock patients were randomly assigned to receive EN supplemented with partially hydrolyzed guar or fiber-free EN. All patients were on mechanical ventilation, antibiotics, and catecholamine therapy. The time to reach the preconceived protein/calorie goals was 5±3 days in the probiotic and 6±3 days in the control group. The difference was not statistically significant (20). In another trial conducted by Tuncay et al., the prevalence of target dose achievement in 21 days intervention was 95.7% in probiotic supplemented and 78.3% in standard EN groups. The difference was not statistically significant (p=0.19) (32).

4.3.2. probiotics

Malik et al. investigated the effect of 7-days microbial cell preparation administration on the return of gut function. Time to return to normal gut function was defined as the time taken to receive a minimum of 80% of the estimated calorie for a consecutive 48-hour period. They reported that patients in the treatment group achieved a faster return of gut function (3±1.75 days vs. 7±1.7 days, p<0.001) (29). Ferrie et al. also investigated the effect of *Lactobacillus rhamnosus GG* on feeding intolerance in critically ill patients with established diarrhea. The frequency of patients with feeding intolerance (tolerate less than 80% of calorie goal for two consecutive days) was 11.1% in the probiotic group and 16.6% in the control group (p= 0.63) (26).

4.4 Effect on diarrhea

4.4.1. Prebiotics

Schultz et al. investigated the effect of pectin on the prevalence of diarrhea in a critical care setting. Diarrhea was more prevalent in the fiber-free/placebo group compared to the fiber-free/pectin group (36% vs. 9%, p=0.31). Diarrhea was also more prevalent in the fiber/placebo than fiber/ pectin group, however, the differences were not statistically significant (55% vs. 9%, p= 0.06) (19). Majid et al. also demonstrated that fiber-enriched EN with additional prebiotic had no significant effect on the prevalence of diarrhea. The prevalence of having at least one day of diarrhea was 92% in the prebiotic and 90% in the placebo group (p=0.99). The number of days of diarrhea was 3.8±3.5 in the placebo and 3.9±4.1 in the prebiotic group (p= 0.94) (28). Tuncay et al. reported that administration of prebiotic-enriched EN was associated with a significant tendency toward lower prevalence (8.7% vs. 56.5%) and faster amelioration of diarrhea (none vs. 52.2% diarrhea prevalence on day 7) (32).

In another trial, the prevalence of having at least one day of diarrhea was 46.1% in the prebiotic and 91.7% in the placebo group (p=0.03). Further, the mean frequency of days of having diarrhea was significantly lower in the fiber group. Besides, in the fiber group, diarrhea occurred in 10.8% of feeding days, compared to 31.5% in the controls (p<0.001) (20).

Rushdi et al. also investigated the effect of soluble guar gum on the number of liquid stools during the four days of intervention. The number of liquid stools was significantly lower at day 4 compared to day 1 in the intervention group, while it was significantly higher in the control group. The number of liquid stools on the fourth day was 1.2±0.7 in the intervention group, compared to 2.1±0.8 in the control group (p<0.01) (21).

4.4.2. probiotics

In the study by Bleichner et al., 128 critically ill patients were randomized to receive *Saccharomyces Boulardii* or placebo capsules. The prevalence of diarrhea was not significantly different between the two groups. However, treatment with *S. boulardii* reduced the mean frequency of diarrhea days per feeding days from 18.9 to 14.2% (p = 0.006). The number of days with diarrhea was also significantly lower in the probiotic group (p=0.001) (18). Barraud et al. also investigated the effect of probiotic administration on the prevalence of diarrhea. They demonstrated no significant effect of probiotic therapy on diarrhea prevalence (55.2% vs. 52.5%, p=0.72) (24). In another RCT, Morrow et al. demonstrated that probiotic administration had no significant effect on the incidence of ICU associated diarrhea. However, the number of days with ICU-associated diarrhea was significantly higher in the placebo group compared to the probiotic group (5.9±3.8 vs. 4.1±3.7, p=0.03) (25). Another trial in 2010 examined the effect of probiotic VSL#3 on diarrhea among 45 critically ill patients. The mean frequency of liquid stool in the probiotic and placebo groups was 0.53±0.54 and 1.05±1.08 episodes per patient per day, respectively (p=0.03) (23). Ferrie et al. also reported that critically ill patients who received probiotic had more diarrhea episodes compared to the control group, although the difference was not statistically significant. Diarrhea days in the 14-day study period was 7.22±3.63 in the probiotic and 5.72±2.88 in the probiotic group (p=0.17) (26).

4.4.3. synbiotics

Knight et al. reported the overall prevalence of diarrhea to be 5% in the synbiotic group, and 7% in the controls (p= 0.59) (22). Shimizu et al. also investigated the effect of daily synbiotic therapy on infectious complications, including enteritis in the intensive care unit. Enteritis was defined as acute onset of continuous liquid stool for more than 12 hours. The results showed that the incidence of enteritis was significantly lower in the synbiotic group (6.3% vs. 27.0%; p < 0.05) (31).

4.5 Effect on length of stay

The effect of pre, pro or synbiotics on ICU and hospital LOS was reported in 10 and 5 trials, respectively (Table 3). Malik et al. demonstrated that probiotic administration was associated with significantly lower ICU LOS (29). Other studies found no significant difference between groups, regarding ICU or hospital LOS (19, 22, 23, 25, 26, 30-33).

**Discussion**
In this systematic review, 15 randomized controlled trials were reviewed to determine the potential of pre, pro, or synbiotics administration to improve enteral feeding tolerance in tube-fed critically ill patients. Gut microbiota is a key regulator of gut function, host metabolism, and appetite. Microbial metabolites, including SCFAs, bile acids, and various neuroactive agents, interact with the GI tract and peripheral tissue through affecting the enteric nervous system and central appetite pathways or altering bile acid signaling (34). These effects result in changes in gastric motility and emptying (35, 36), which may reduce enteral feeding intolerance. Besides, gut microbiota can influence intestinal barrier function and modulate the immune system, thus indirectly affect metabolism and eating behavior (16).

5.1 Effect on energy intake or feed volume

We found six studies that evaluated the effect of pre, pro or synbiotics on enteral feeding volume or energy intake. Considering the application of probiotics or synbiotics, no significant effect was reported. Only 2 of 4 studies, that used prebiotics (one soluble guar gum for 4 days and the other FOS for 21 days) in the intervention group, found significant beneficial effects (21, 32). It should be noted that in both of these studies, patients in the intervention group received significantly more volume and energy on the first day. Therefore, it seems that the significant difference between the two groups in terms of received feed volume and energy at the end of the study may not be merely attributed to the effect of prebiotics.

5.2 Effect on target calorie achievement

Four trials evaluated the effect of pre or probiotics on frequency or time to achieve the target calorie. All studies but one found no significant effect. In this study, probiotic administration for seven consecutive days was associated with a significantly faster return of the gut function (29). The included studies were heterogeneous in population features, intervention, duration, eligibility criteria, and EN protocol. Thus, the conflicting results may be attributed to these factors. It is also believed that the beneficial effect of probiotics or synbiotics could be highly strain-specific.

5.3 Effect on diarrhea

In the critical care setting, diarrhea is the most common gastrointestinal complication of EN (37), which may result in several unfavorable clinical conditions including enteral nutrition cessation and exacerbation of undernutrition (32). Factors that contribute to the pathogenesis of diarrhea include altered physiological responses due to EN, antibiotics administration, and altered gut microbiota function (38). Therefore, gut microbiota manipulation may be an approach for the prevention and management of diarrhea in the critical care setting. For example, gut microbiota manipulation can reverse abnormal colonic water secretion by SCFAs production (39), alter colonic motor activity (40), and interfere with pathogen colonization in the gut, which protects against diarrhea (38).

The effect of prebiotics on diarrhea was evaluated in five clinical trials (19-21, 28, 32). Four studies investigated the effect of prebiotic on the prevalence of diarrhea. While two studies found a significant (20, 32) and one a non-significant decrease (19), the other reported a non-significant increase (28). The number of days of diarrhea was also investigated in two studies, one of which reported a significant decrease (20), while the other found a non-significant increase(28). The number of liquid stools was also reported to be lower in the prebiotic group in one trial (21).

It should be noticed that water-soluble fiber like pectin or guar gum exhibits antidiarrheal effect by two mechanisms: 1) production of SCFAs and maintaining gut microbiota homeostasis or 2) reuptake of water and electrolytes (41). The beneficial effect of water-soluble fibers on SCFAs production is well documented in non-critically ill patients and healthy subjects, but it is not clearly observed in critically ill patients(41). So, the positive effect of water-soluble fibers in the mentioned studies may be attributed to the increased reuptake of water and electrolytes, not necessarily acting as prebiotics.

Regarding the effect of probiotics on the incidence of diarrhea, two studies reported a trend towards reduced diarrhea incidence in the probiotic group (18, 25), and one reported a non-significant increase (24). The effect of probiotic administration on diarrhea days was demonstrated in three of the included trials. Two of them reported a significant decrease in diarrhea duration (18, 25), while one reported a non-significant increase (26). In the probiotic group, the number of liquid stools per patient per day was reported to be significantly lower in one study (23) but, loose stools were non-significantly more in another study (26).

A non-significant decrease in the prevalence of diarrhea (22) and a significant decrease in the incidence of enteritis (31) was reported to be associated with synbiotic administration.

5.4 Effect on length of stay

All but one study found no beneficial effects for gut microbiota manipulation on clinical endpoints, including LOS in hospital and ICU. A recent systematic review and meta-analysis by Manzanares et al. also showed that despite the beneficial effects of probiotic and synbiotic administration on overall infections and ventilator-associated pneumonia, these agents had no significant effect on LOS in hospital or ICU (42).

To the best of our knowledge, this systematic review was the first study to review the effect of pre, pro, and synbiotics on feeding tolerance in enterally-fed critically ill patients. As we assessed relevant outcomes in a heterogeneous ICU population, our results could be attributed to a broad spectrum of critically ill patients with sepsis, trauma, or other medical conditions. Although, the inclusion of diverse patient groups in this systematic review may be considered as a limitation for interpretation of the results. There was also great diversity in the type of administered prebiotic or probiotic strains, duration of treatment, and dose. This heterogeneity also made it impossible to quantitatively evaluate the results. Furthermore, most of the included studies reported the energy intake or feeding tolerance as a secondary outcome, not mentioning the EN protocols, while the reported EN protocols were heterogeneous in other studies.
Conclusion
Overall, the heterogeneity in studied product format, ICU patient populations, and study designs make it difficult to draw any general conclusion on the effect of pre, pro, or synbiotics on feeding tolerance of critically ill tube-fed patients. We suggest more new well-designed trials that assess feeding tolerance as a primary endpoint with a unified definition and an invariable enteral nutrition protocol that would make it possible to compare the obtained results. New trials should aim to demonstrate the beneficial composition of supplements, dose, and duration to have beneficial effects. There is, moreover, a need to conduct studies that clearly establish the molecular mechanisms by which gut microbiota manipulation is attributed to feeding tolerance in critically ill patients.

Abbreviations
CCK: Cholecystokinin, EN: Enteral nutrition, FOS: fructo-oligosaccharide, GI: Gastrointestinal, GRV: Gastric residual volume, ICU: Intensive Care Unit, LOS: Length of stay, PICO: population, intervention, comparison, outcome and study design, PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis, PYY: Peptide YY, RCT: Randomized controlled trials, SCFAs: Short chain fatty acids

Declarations
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Availability of data and material
The datasets generated and/or analyzed during the current study are not publicly available, but may be available from the corresponding author on reasonable request.

Acknowledgement
The support provided by Mashhad University of Medical Sciences (MUMS) to conduct this study is highly acknowledged. We also appreciate the support of the Clinical Research Development Unit of Akbar Hospital.

Funding
This research is funded by vice chancellery for research of Mashhad University of Medical Sciences (MUMS).

Competing interests
No conflict of interest has been declared by the authors.

Authors' contribution
NS: conceptualization, methodology, investigation, writing the original draft AJE: methodology, investigation, review and editing AS: review and editing, supervision MKR: methodology, formal analysis RR: conceptualization, review and editing MS: project administration, supervision.

References
1. Sharma K, Mogensen KM, Robinson MK. Pathophysiology of critical illness and role of nutrition. Nutr Clin Pract. 2019;34(1):12-22.
2. Hoffer LJ, Bistrian BR. Nutrition in critical illness: a current conundrum. F1000Research. 2016;5.
3. Heinonen T, Ferrie S, Ferguson C. Gut function in the intensive care unit—What is ‘normal’? Aust Crit Care. 2020;33(2):103-104.
4. Moron R, Galvez J, Colmenero M, Anderson P, Cabeza J, Rodriguez-Cabezas ME. The Importance of the Microbiome in Critically Ill Patients: Role of Nutrition. Nutrients. 2019;11(12):3002.
5. Kitsios GD, Morowitz MJ, Dickson RP, Huffnagle GB, McVerry BJ, Morris A. Dysbiosis in the intensive care unit: Microbiome science coming to the bedside. J Crit Care. 2017;38:84-91.
6. Blaser AR, Starkopf J, Alhazzani W, Berger MM, Csaer MP, Deane AM, et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive care med. 2017;43(3):380-98.
7. McClave SA, Gudolni J, Nagengast A, Marsano LS, Bandy K, Marindale RG. Gastrointestinal Dysfunction and Feeding Intolerance in Critical Illness: Do We Need an Objective Scoring System? Curr Gastroenterol Rep. 2020;22(1):1.
8. Blaser AR, Starkopf J, Kirsimägi Ü, Deane A. Definition, prevalence, and outcome of feeding intolerance in intensive care: a systematic review and meta-analysis. Acta Anaesthesiol Scand. 2014;58(8):914-22.
9. Chen W-T, Du M-J, Chen Y-Z, Yuan D-Q. Factors influencing feeding intolerance in critically ill patients during enteral nutrition. Int J Clin Exp Med. 2019;12(7):7999-8003.
10. Roberfroid M.J.BjoN. Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr.1998;80(S2):S197-S202.
11. Verdu E. Probiotics effects on gastrointestinal function: beyond the gut? J Neurogastroenterol Motil. 2009;21(5):477-80.
12. Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World journal of gastroenterology. 2016;22(7):2219.
13. Butt RL, Volkoff H. Gut microbiota and energy homeostasis in fish. Front Endocrinol. 2019;10:9.
14. Cani PD, Geurts L, Matamoros S, Plovier H, Duparc T. Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond. Diabetes & metab. 2014;40(4):246-57.
15. Caricili AM, Saad MJ. The role of gut microbiota on insulin resistance. Nutrients. 2013;5(3):829-51.
16. Spiljar M, Merkler D, Trajkovski M. The immune system bridges the gut microbiota with systemic energy homeostasis: focus on TLRs, mucosal barrier, and SCFAs. Front Immunol. 2018;7:1353.
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS med. 2009;6(7):e1000100.
18. Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Intensive care med. 1997;23(5):517-23.
19. Sholtz AA, Taylor BA-HR, Gillis DE, Wilkins M. Effects of pectin on diarrhea in critically ill tube-fed patients receiving antibiotics. Am J Crit Care. 2000;9(6):403.
20. Spaten H, Dittoer M, Van Malderen C, Opdenacker G, Suys E, Huygens L. Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective, double-blind, randomized, and controlled trial. Clin Nutr. 2001;20(4):301-5.
21. Rushdi TA, Pichard C, Khater YH. Control of diarrhea by fiber-enriched diet in ICU patients on enteral nutrition: a prospective randomized controlled trial. Clin nutr. 2004;23(6):1344-52.
22. Knight DJW, Gardiner D, Banks A, Snape SE, Weston VC, Bengmark S, et al. Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: A randomised, double-blind, placebo-controlled trial. Intensive Care Med. 2009;35(5):854-61.
23. Frohmader TJ, Chaboyer WP, Robertson IK, Gowardman J. Decrease in frequency of liquid stool in enterally fed critically ill patients given the multispecies probiotic VSL#3: a pilot trial. Am j crit care. 2010;19(3):e1-11.
24. Barraud D, Blard C, Hein F, Marçon Q, Cravoisy A, Nace L, et al. Probiotics in the critically ill patient: A double blind, randomized, placebo-controlled trial. Intensive Care Med. 2010;36(9):1540-7.
25. Murray LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182(8):1058-64.
26. Ferrie S, Daley M. Lactobacillus GG as treatment for diarrhea during enteral feeding in critical illness: randomized controlled trial. J Parenter Enteral Nutr. 2011;35(1):43-9.
27. Sanaie S, Ebrahim-Mameghani M, Hamishehkar H, Mojtahedzadeh M, Mahmooodpoor A. Effect of a multispecies Probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2014;19(9):827-33.
28. Majid HA, Cole J, Emery PW, Whelan K. Additional oligofructose/inulin does not increase faecal bifidobacteria in critically ill patients receiving enteral nutrition: a randomised controlled trial. Clin nutr. 2014;33(6):966-72.
29. Malik AA, Rajandram R, Tah PC, Hakumat-Rai VR, Chin KF. Microbial cell preparation in enteral feeding in critically ill patients: A randomized, double-blind, placebo-controlled clinical trial. J Crit Care. 2016;32:182-8.
30. Fazilaty Z, Chenari H, Shariatpanahi ZV. Effect of β-glucan on serum levels of IL-12, hs-CRP, and clinical outcomes in multiple-trauma patients: A prospective randomized study. Ulus Travma Acil Cerrahi Derg. 2018;24(4):287-93.
31. Shimizu K, Yamada T, Ogura H, Mohri T, Kiguchi T, Fujimi S, et al. Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2014;19(9):827-33.
32. Tuncay P, Arpaci F, Doganay M, Erdem D, Sahna A, Ergun H, et al. Use of standard enteral formula versus enteric formula with probiotic content in pneumonia in patients with sepsis: a randomized controlled trial. Crit care. 2018;22(1):239.
33. Shimizu K, Yamada T, Ogura H, Mohri T, Kiguchi T, Fujimi S, et al. Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2014;19(9):827-33.
34. van de Wouw M, Schellekens H, Dinan TG, Cryan JF. Microbiota-gut-brain axis: modulator of host metabolism and appetite. J Nutr. 2017;147(5):727-45.
35. Russo F, Clemente C, Linsalata M, Chiloiro M, Orlando A, Marconi E, et al. Effects of a diet with inulin-enriched pasta on gut peptides and gastric emptying rates in healthy young volunteers. Eur J Nutr. 2011;50(4):271-7.
36. Davani-Davari D, Naghadarijou M, Karimzadeh I, Seifan M, Mohkam M, Masoumi SJ, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods. 2019;8(3):92.
37. Monjejo JC. Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study. Crit care med. 1999;27(8):1447-53.
38. Whelan K, Schneider SM. Mechanisms, prevention, and management of diarrhea in enteral nutrition. Curr Opin Gastroenterol. 2011;27(2):152-9.
Table 1 PICOS criteria for inclusion and exclusion of criteria

| Parameter     | Inclusion criteria                                                                 | Exclusion criteria              |
|---------------|------------------------------------------------------------------------------------|---------------------------------|
| Population    | Adult tube-fed critically ill patients                                             | Partial EN                     |
| Intervention  | Supplementation with pre, pro or synbiotics                                       |                                 |
| Comparison    | Placebo or nothing                                                                |                                 |
| Outcome       | Enteral feed volume, Time to reach full enteral nutrition, the prevalence of feed intolerance and related GI complications (diarrhea, distention, high residual volume) |                                 |
| Study design  | Randomized controlled trials                                                      | In vitro studies                |

Abbreviations: EN, enteral nutrition; GI, gastrointestinal

Table 2 Randomized controlled trials evaluating the effect of pre, pro or synbiotics on feeding tolerance of enterally-fed critically ill patients
| Author, Year | Population | Design | JADAD score | EN protocol | Delivery vehicle | Intervention /dose/duration | control |
|-------------|------------|--------|-------------|-------------|------------------|-----------------------------|---------|
| Bleicher, 1997 (17) | ICU patients n=128 | parallel | 5 | NR | NGT or jejunostomy | EN (intact protein standard diet without fiber or lactose) + S.boulardii /500 mg four times a day/limited to 21 days or to the withdrawal of EN | EN (intact protein standard diet without fiber or lactose) + placebo |
| Schultz, 2000 (18) | ICU patients n=44 | parallel | 2 | NR | Tube feeding | Fiber containing formula+ pectin or fiber-free formula +pectin/ 20 ml, twice daily/ 6 days | Fiber containing formula+ placebo Or fiber-free formula + placebo |
| Spapen, 2001(19) | ICU patients with severe sepsis or septic shock n= 25 | parallel | 3 | Start: first 24h, 25cc/h. Increase 25-35 cc/h to 80% target | NGT | EN+ partially hydrolyzed guar/ 22g/l / a maximum of 21 days or to the withdrawal of EN | Fiber free EN |
| Rushdi, 2004 (20) | ICU patients with persistent diarrhea n=20 | parallel | 3 | Start: first 18-24h. Target:25-35 kcal/kg. First day:50%, second day:75%, third day:100% | NJT | EN+ 2% soluble guar gum (Benefiber)/ 4 days | Fiber free EN |
| Knight, 2009 (21) | ICU patients n= 259 | parallel | 5 | start: 30cc/h, max:80cc/h. increase or decrease according to GRV | NGT/ OGT | EN (Nutrison Energy) + Synbiotic 2000 FORTE / twice a day/ to the earliest of the following time point:28 days after admission, death or discharge | EN (Nutrison Energy) + placebo |
| Frohmader, 2010 (22) | ICU patients n= 45 | parallel | 5 | Start: first 24h, 20cc/h, increase: 20cc/4h to target. Target:25-35 Kcal/kg | NGT/ OGT/ nasojejunostomy | Fiber free EN+ probiotic (VSL#3) / twice a day/ mean of 11.9 days | Fiber free EN+ placebo |
| Barraud, 2010 (23) | ICU patients with MV n=167 | parallel | 5 | Starting in the first 24h, 10 Kcal/kg, increase to 30-35 Kcal/kg | NGT | EN + multi- strain probiotic (Ergyphilus)/ once a day/ until successful weaning (maximum of 28 days) | EN + placebo |
| Morrow, 2010 (24) | ICU patients with MV n=167 | parallel | 5 | NR | NGT | EN + probiotic (Lactobacillus rhamnosus GG) / twice a day/ | EN+ inulin-based placebo |
| Ferrie, 2011 (25) | ICU patients with diarrhea n= 36 | parallel | 5 | NR | Gastric tube | Fiber containing EN+ probiotic (inulin-based Lactobacillus GG)/twice a day/ 7 days | Fiber containing EN+ placebo (inulin) |
| Sanaei, 2014 (26) | ICU patient n= 40 | parallel | 5 | Start in first 24h, 25cc/h. increase 25cc/4h to target. Target:25-30 Kcal/kg | NGT | Fiber containing EN+ probiotic (VSL#3)/ twice daily/ 7 days | Fiber containing EN+ placebo |
| Majid, 2014 (27) | ICU patients n= 22 | parallel | 5 | Energy estimation based on Schofield equation | NGT | Fiber containing EN+ additional oligofructose/inulin/ 7g per day/ 7 days | Fiber containing EN+ placebo |
| Malik, 2016 (28) | ICU patients n= 60 | parallel | 5 | 25 Kcal/kg. start in first 24-48h, with GRV management | NGT | EN+ multi- strain probiotic/ twice a day/ 7 days | EN+ placebo |
| Fazilaty, 2018 (29) | Multiple trauma ICU patients n= 40 | parallel | 5 | Goal:25-30Kcal/Kg, 75% in the 48h | NGT | EN+ prebiotic (oat β-glucan)/ 3g per day/ 21 days | EN+ placebo (maltodextrin) |
| Shimizu, 2018 (30) | Septic ICU patients with MV | parallel | 3 | Start: 20cc/h, increase: 20cc/h/day to target. Target:25-30 Kcal/kg | NGT | EN + multi- strain probiotic (Yakult BL Seichoyaku) 3 g per day/ prebiotic (galactooligosaccharides) 10g per day/ until EN stop | EN |
| Tuncay, 2018 (31) | Neurocritical care patients n=46 | parallel | 1 | start:10cc/h, increase:10cc/8h till 20cc/h. | NGT | EN with prebiotic content/ 21 days | EN |
Table 3 Reported feeding tolerance-related outcomes in RCTs evaluating the effect of pre, pro or synbiotics on feeding tolerance of enterally-fed critically ill patients
| Study                  | Energy intake | Achieving the target calorie | Diarrhea | Length of stay |
|-----------------------|---------------|------------------------------|----------|----------------|
|                       | intervention  | control                      | intervention | control       |
|                       |               |                              | intervention | control       |
|                       |               |                              | intervention | control       |
|                       |               |                              | intervention | control       |
| **Bleichner, 1997 (17)** | NR | NR | NR | NR | Prevalence: 18/64 (24%) days w/ diarrhea per feeding days: 14.2% | Prevalence: 24/64 (38%) days w/ diarrhea per feeding days: 18.9% |
| **Schultz, 2000 (18)** | Mean± | Mean± | NR | NR | Prevalence: 1/11 (9%) | Prevalence: 4/11 (36%) |
| **Spapen, 2001 (19)** | NR | NR | Time to: 5±3 days | Time to: 6±3 days | Prevalence: 6/13 (46%) Days w diarrhea per feeding days: 16/148 (10.8%) | Prevalence: 11/12 (92%) Days w diarrhea per feeding days: 46/146 (31.5%) |
| **Rushdi, 2004 (20)** | Day 1-4 | Day 1-4 | NR | NR | Prevalence: 1/11 (9%) | Prevalence: 4/11 (36%) |
| **Knight, 2009 (21)** | Day1-7 | Day1-7 | NR | NR | Prevalence: 7/130 (5%) | Prevalence: 9/129 (7%) |
| **Frohmder, 2010 (22)** | NR | NR | NR | NR | Frequency of liquid stools: 0.53±0.54 | Frequency of liquid stools: 1.05±1.08 |
| **Barraud, 2010 (23)** | NR | NR | NR | NR | Prevalence: 48/87 (55.2) | Prevalence: 42/80 (52.5) |
| **Morrow, 2010 (24)** | NR | NR | NR | NR | Prevalence: 44/70 (62.9) Days w/ diarrhea: 5.9±3.8 | Prevalence: 42/68 (61.8) Days w/ diarrhea: 4.1±3.7 |
| **Ferrie, 2011 (25)** | NR | NR | Prevalence 16/18 (88.8) | Prevalence 15/18 (83.3) | Diarrhea duration: 7.22±3.63 Loose stool per day: 3.14±1.23 | Diarrhea duration: 5.72±2.88 Loose stool per day: 3±1.2 |
| **Sanaei, 2014 (26)** | Mean± | Mean± | NR | NR | Prevalence: 48/87 (55.2) | Prevalence: 42/80 (52.5) |
| **Majid, 2014 (27)** | NR | NR | NR | NR | Prevalence: 11/12 (92%) Days w/ diarrhea: 3.9±4.1 | Prevalence: 9/10 (90) Days w/ diarrhea: 3.8±3.5 |
| **Malik, 2016 (28)** | NR | NR | Time to: 3±1.75 days | Time to: 3±1.7 days | NR | NR |
| **Fazilaty, 2018 (29)** | Mean± | Mean± | NR | NR | Prevalence: 11/12 (92%) Days w/ diarrhea: 3.9±4.1 | Prevalence: 9/10 (90) Days w/ diarrhea: 3.8±3.5 |
| **Shimizu, 2018 (30)** | NR | NR | NR | NR | Incidence of enteritis: 2/35 (6.3) | Incidence of enteritis: 10/37 (27) |
| **Tuncay, 2018 (31)** | Day 1 and 21 | Day 1 and 21 | Prevalence 22 (95.7) | Prevalence 18 (78.3) | Prevalence: 8.7% | Prevalence: 56.5% |

**Abbreviations:** NR, not reported; ICU, intensive care unit.

Mean energy intake was reported for the entire intervention duration.